BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bradbury CA, Lawler PR, Stanworth SJ, McVerry BJ, McQuilten Z, Higgins AM, Mouncey PR, Al-Beidh F, Rowan KM, Berry LR, Lorenzi E, Zarychanski R, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Bhimani Z, Bihari S, Bonten MJM, Brunkhorst FM, Buzgau A, Buxton M, Carrier M, Cheng AC, Cove M, Detry MA, Estcourt LJ, Fitzgerald M, Girard TD, Goligher EC, Goossens H, Haniffa R, Hills T, Huang DT, Horvat CM, Hunt BJ, Ichihara N, Lamontagne F, Leavis HL, Linstrum KM, Litton E, Marshall JC, McAuley DF, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Morpeth SC, Murthy S, Neal MD, Nichol AD, Parke RL, Parker JC, Reyes L, Saito H, Santos MS, Saunders CT, Serpa-Neto A, Seymour CW, Shankar-Hari M, Singh V, Tolppa T, Turgeon AF, Turner AM, van de Veerdonk FL, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Derde LPG, Webb SA, Gordon AC; REMAP-CAP Writing Committee for the REMAP-CAP Investigators. Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA 2022. [PMID: 35315874 DOI: 10.1001/jama.2022.2910] [Cited by in Crossref: 15] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Ali RM, Tharwat AI, Labib HA. Effect of Aspirin Use on clinical Outcome among Critically Ill Patients with COVID- 19. Egyptian Journal of Anaesthesia 2022;38:629-635. [DOI: 10.1080/11101849.2022.2139104] [Reference Citation Analysis]
2 Mujahid N, Rajan A, Abul Y, Vura NVRK, Neupane I, Laplante K, Gravenstein S. When to opt for preemptive anticoagulation with SARS-CoV-2 infection in the long-term care facilities. Aging Clin Exp Res 2022. [DOI: 10.1007/s40520-022-02304-8] [Reference Citation Analysis]
3 Khimani F, Wolf AJ, Yoon B, Blancke A, Gerhart C, Endsley D, Dougherty A, Ray AK, Yango AF, Flynn SD, Lip GY, Gonzalez SA, Sathyamoorthy M. Therapeutic considerations for prevention and treatment of thrombotic events in COVID-19. Thrombosis Update 2022. [DOI: 10.1016/j.tru.2022.100126] [Reference Citation Analysis]
4 Jin S, Luo J, Wu X, Wang D, Zhang W, Li Z. A case of multiple thrombosis and septic shock in a critically ill patient with Omicron infection. J Infect Public Health 2022;15:1321-5. [PMID: 36283343 DOI: 10.1016/j.jiph.2022.10.014] [Reference Citation Analysis]
5 Dahmer M, Jennings A, Parker M, Sanchez-pinto LN, Thompson A, Traube C, Zimmerman JJ. Pediatric Critical Care in the Twenty-first Century and Beyond. Critical Care Clinics 2022. [DOI: 10.1016/j.ccc.2022.09.013] [Reference Citation Analysis]
6 Schulman S, Sholzberg M, Spyropoulos AC, Zarychanski R. "ISTH guidelines for antithrombotic treatment in COVID-19": Reply. J Thromb Haemost 2022;20:2710-1. [PMID: 36271457 DOI: 10.1111/jth.15854] [Reference Citation Analysis]
7 Murakami N, Hayden R, Hills T, Al-Samkari H, Casey J, Del Sorbo L, Lawler PR, Sise ME, Leaf DE. Therapeutic advances in COVID-19. Nat Rev Nephrol 2022. [PMID: 36253508 DOI: 10.1038/s41581-022-00642-4] [Reference Citation Analysis]
8 Arabi YM, Myatra SN, Lobo SM. Surging ICU during COVID-19 pandemic: an overview. Curr Opin Crit Care 2022. [PMID: 36226716 DOI: 10.1097/MCC.0000000000001001] [Reference Citation Analysis]
9 Ortega-Paz L, Talasaz AH, Sadeghipour P, Potpara TS, Aronow HD, Jara-Palomares L, Sholzberg M, Angiolillo DJ, Lip GYH, Bikdeli B. COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment. Semin Thromb Hemost 2022. [PMID: 36223804 DOI: 10.1055/s-0042-1757634] [Reference Citation Analysis]
10 Kyriakoulis KG, Dimakakos E, Kyriakoulis IG, Catalano M, Spyropoulos AC, Schulman S, Douketis J, Falanga A, Maraveyas A, Olinic D, Belch J, Gerotziafas G, Syrigos K, Kollias A; COVID-19 Thrombosis Collaborative Group, Endorsed by VAS-European Independent Foundation in Angiology/Vascular Medicine, UEMS Division of Angiology/Vascular Medicine/and ESVM-European Society of Vascular Medicine and Supported by the Balkan Working Group. Practical Recommendations for Optimal Thromboprophylaxis in Patients with COVID-19: A Consensus Statement Based on Available Clinical Trials. JCM 2022;11:5997. [DOI: 10.3390/jcm11205997] [Reference Citation Analysis]
11 Su W, Miao H, Guo Z, Chen Q, Huang T, Ding R. Associations between the use of aspirin or other antiplatelet drugs and all-cause mortality among patients with COVID-19: A meta-analysis. Front Pharmacol 2022;13:989903. [DOI: 10.3389/fphar.2022.989903] [Reference Citation Analysis]
12 Eikelboom JW, Jolly SS, Belley-cote EP, Whitlock RP, Rangarajan S, Xu L, Heenan L, Bangdiwala SI, Luz Diaz M, Diaz R, Yusufali A, Kumar Sharma S, Tarhuni WM, Hassany M, Avezum A, Harper W, Wasserman S, Almas A, Drapkina O, Felix C, Lopes RD, Berwanger O, Lopez-jaramillo P, Anand SS, Bosch J, Choudhri S, Farkouh ME, Loeb M, Yusuf S. Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. The Lancet Respiratory Medicine 2022. [DOI: 10.1016/s2213-2600(22)00298-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Brem FL, Tayef TAA, Rasras H, Mahi OE, Ouafi NE, Zakaria B. Concomitant renal and splenic infarctions in a COVID-19-patient with a catastrophic thrombotic syndrome. Radiology Case Reports 2022;17:4030-4033. [DOI: 10.1016/j.radcr.2022.06.076] [Reference Citation Analysis]
14 Xiang M, Wu X, Jing H, Liu L, Wang C, Wang Y, Novakovic VA, Shi J. The impact of platelets on pulmonary microcirculation throughout COVID-19 and its persistent activating factors. Front Immunol 2022;13:955654. [DOI: 10.3389/fimmu.2022.955654] [Reference Citation Analysis]
15 Zong X, Wang X, Liu Y, Li Z, Wang W, Wei D, Chen Z. Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials. Front Med 2022;9. [DOI: 10.3389/fmed.2022.965790] [Reference Citation Analysis]
16 Duo H, Li Y, Sun Y, Wei L, Wang Z, Fang F, Zhong Y, Huang J, Luo L, Peng Z, Pan H. Effect of therapeutic versus prophylactic anticoagulation therapy on clinical outcomes in COVID-19 patients: a systematic review with an updated meta-analysis. Thromb J 2022;20:47. [PMID: 35999599 DOI: 10.1186/s12959-022-00408-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Liu L, Jing H, Wu X, Xiang M, Novakovic VA, Wang S, Shi J. The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.957006] [Reference Citation Analysis]
18 Zhang H, Lao Q, Zhang J, Zhu J. Coagulopathy in COVID-19 and anticoagulation clinical trials. Best Practice & Research Clinical Haematology 2022. [DOI: 10.1016/j.beha.2022.101377] [Reference Citation Analysis]
19 Toner P, Mcauley DF, O’kane CM. Response. Chest 2022;161:e392-e393. [DOI: 10.1016/j.chest.2022.03.005] [Reference Citation Analysis]
20 Ng SM, Pan J, Mouyis K, Kondapally Seshasai SR, Kapil V, Rice KM, Gupta AK. Quantifying the Excess Risk of Adverse COVID-19 Outcomes in Unvaccinated Individuals With Diabetes Mellitus, Hypertension, Ischaemic Heart Disease or Myocardial Injury: A Meta-Analysis. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.871151] [Reference Citation Analysis]